Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 19 Jun 2024 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 18 Jun 2024 |
| Genmab A/S has published its Articles of Association | 17 Jun 2024 |
| Transactions in Connection with Share Buy-back Program | 17 Jun 2024 |
| Grant of Restricted Stock Units and Warrants to Employees in Genmab | 12 Jun 2024 |